tnf

TNF-α agonistic 1, a TNF-α agonistic compound, could induce cells to secrete TNF- α.

TNF/IFNγ-IN-1 (TGA) is a dual inhibitor of TNF and IFN-γ. TNF/IFNγ-IN-1 has potential antioxidant and anti-inflammatory activities for neurodegenerative diseases such as Alzheimer.

TNF-α-IN-1 is a TNF-α inhibitor.

TNF-α (31-45), human, is a peptide of tumor necrosis factor-α.

TNF-α-IN-2 is an effective and orally active TNFα inhibitor that distorts the TNFα trimer upon binding, causing abnormal signal transduction when it binds to TNFR1, and can be used to study rheumatoid arthritis.

TNF-α antagonist is an exocyclic peptide that mimics the critical TNF-α recognition loop on TNF receptor I complex and, thus, prevents ligand interaction with the receptor. By blocking the TNF receptor ligand contact site, this peptide interferes with both activating receptor activator of NF-κB (RANK) and TNF-α's recruitment and activation of osteoclasts. TNF-α antagonist has been used to block bone resorption in the study of systemic bone loss in rheumatoid arthritis and inflammatory bone destruction.

TNF-α-IN-6 is an orally efficacious, allosteric inhibitor of TNFα (K_D = 6.8 nM).

TNF-α-IN-9 is an NDM-1 inhibitor-3 analog and is a TNF-α inhibitor.TNF-α-IN-9 shows low inhibitory activity.

Anti-Mouse TNF alpha Antibody (TN3-19.12) is a mouse-derived IgG antibody against TNF alpha.

Human TNF alpha (46-65) peptide.

TNF-α (31-45), human acetate is a peptide of tumor necrosis factor-α.

Anti-Fibronectin Antibody (L19-TNF) is a human-derived antibody expressed in CHO cells, specifically targeting Fibronectin. It has a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 144.14 kDa. For its isotype control, please refer to HumanIgG4kappa, Isotype Control.

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

TNF-α (31-45), human (TFA) is a peptide of tumor necrosis factor-α.

TNF-α (46-65), human (TFA) is a peptide of human TNF-α.

TAPI-2 is a broad-spectrum inhibitor of MMP (IC50: 20 μM), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM).

Acetylcysteine (NAC) is an N-acetyl derivative of cysteine, a ROS inhibitor and mucolytic agent. Acetylcysteine induces apoptosis, can be used to reduce mucus thickness, and has anti-influenza viral activity.

R-7050 (TNF-α Antagonist III) is a tumor necrosis factor receptor (TNFR) antagonist that exhibits heightened selectivity for TNFα.

TIC10 (ONC-201) inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.

Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

5-O-Caffeoylshikimic acid shows anti-oxidative activity; it also shows anti-inflammatory activity, the underlying mechanism was associated with downregulation of nuclear factor-κB.